M. J. Uprichard

Medicine · Health Sciences

8h-index727citations19works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(13), Protein Degradation and Inhibitors(5), Neuroendocrine Tumor Research Advances(4), Virus-based gene therapy research(3), CAR-T cell therapy research(3)

Publications19 total

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
BMC Cancer·2009· 78 citedOpen Access
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Clinical Oncology·2009· 88 cited
Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
Journal of Clinical Oncology·2007· 21 cited
Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL
Journal of Clinical Oncology·2006· 5 cited
Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma
Journal of Clinical Oncology·2006· 10 cited
Phase I Trial of PT-100 (PT-100), A Cytokine-Inducing Small Molecule, Following Chemotherapy for Solid Tumor Malignancy
Cancer Investigation·2006· 30 cited
Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.
Blood·2005· 1 cited
A Phase 2 Study of Talabostat in Patients With Stage IV Melanoma
Journal of Immunotherapy·2005· 1 cited
Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC
Journal of Clinical Oncology·2005· 6 cited
Phase 2 trial of talabostat in stage IV melanoma
Journal of Clinical Oncology·2005· 8 cited
Phase 2 study of talabostat and cisplatin in stage IV melanoma
Journal of Clinical Oncology·2005· 7 cited
Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.
Blood·2004· 8 cited
Phase 1 Rising Multiple-Dose Study of Talabostat (PT-100) in Healthy Subjects.
Blood·2004· 6 cited
Phase 1 Rising Single-Dose Study of Talabostat (PT-100) in Healthy Volunteers
Journal of Immunotherapy·2004· 2 cited
A phase 1 trial of PT-100 in patients receiving myelosuppressive chemotherapy
Journal of Clinical Oncology·2004· 1 cited
A phase 1 trial of PT-100 in patients receiving myelosuppressive chemotherapy
Journal of Clinical Oncology·2004· 1 cited
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology·2003· 144 cited
Phase I I T rial o f I ntravenous C I-1042 i n P atients W ith Metastatic C olorectal C ancer
2003
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
PubMed·2002· 310 cited

Frequent Co-authors

Casey Cunningham(8), Eric Haltom(8), Donald Richards(5), Barry Jones(5), John Nemunaitis(5), Neil Senzer(4), Steven O’Day(3), Gary Frenette(3), Khuda Dad Khan(3), L. Gregoire(3), Oday Hamid(2), Mary Varterasian(2), Scott Wadler(2), J. Randolph Hecht(2), Evanthia Galanis(2), Charles Omer(2), Paul Bycott(2), Robert C. Hackman(2), Anthony F. Shields(2), Charles Cunningham(2)